- Press releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Analyst Coverage
- Financial Reports
- Financial calendar
- DCprime Merger Information
- Secured Rights issue 2018
- Secured Rights issue 2017
The members of the nomination committee shall, irrespective of how they are appointed, attend to the interests of all shareholders. The annual general meeting resolves how the nomination shall be appointed.
Nomination Committee of the Annual General Meeting 2021
In accordance with the principles of appointing the nomination committee, adopted by the annual general meeting of 28 April 2020, the chairman of the board of directors has contacted the major shareholders in order to appoint a nomination committee. The nomination committee of Immunicum consist of the four members appointed by the four largest shareholders that have accepted the invitation to participate in the nomination committee.
The nomination committee before the annual general meeting of 2021 is convened by the interim chairman of Immunicum’s board of directors Christine Lind and consists of Martin Lindström (appointed by Loggen Invest AB), Jannis Kitsakis (appointed by The Fourth Swedish National Pension Fund) Erik Esveld (appointed by Van Herk Investments BV) and Jamal El-Mosleh, (appointed by Holger Blomstrand byggnads AB). The nomination committee’s assignment is to prepare the following proposals to the annual general meeting of 2021: (i) proposal of nomination of the chairman of the annual general meeting; (ii) proposal of nomination of board members; (iii) proposal of nomination of the chairman of the board of directors; (iv) proposal of the remuneration to the board of directors; (v) proposal of nomination of auditors (if instructed pursuant to Chapter 8 Section 49 b Paragraph 2 of the Companies Act); (vi) proposal of remuneration to the auditors; and (vii) proposal of principles of the nomination committee before the annual general meeting of 2022.
The annual general meeting in Immunicum will be held on 4 may 2021.
Shareholders who wish to leave proposal to the nomination committee can do so by email to email@example.com or by letter to Immunicum AB (publ), Att: Valberedningen, Östermalmstorg 5, 114 42 Stockholm